"OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects

Arribas, Jose R., M.D.200 enrolled

Overview

Lopinavir/ritonavir monotherapy may maintain virologic suppression in patients who have been undetectable for six months while on triple drug antiretroviral therapy. Lopinavir/ritonavir pharmacokinetics might prevent resistance development in patients who experience virological rebound after single-drug simplification.

Primary Study Objective: Efficacy and durability of switching to lopinavir/ritonavir single-drug HAART compared to maintaining therapy based on lopinavir/ritonavir and two nucleosides Secondary Study Objective(s): * Safety (related drug AEs/SAEs and laboratory anomalies G3/4) through 48 w. * Resistance profile on patients with sustained virological failure * QOL comparing stopping nucleosides versus continuing therapy * Pharmaco-economic analysis comparing treatment cost between the 2 study arms. * Predicting factors of failure in the stopping nucleosides arm Subject Population: 200 patients Study Design: RANDOMIZATION: Patients are randomized (1:1) either to continue under the same treatment or stop nucleosides as follows: * Stopping nucleosides arm: Lopinavir/r alone. * Continuing arm: Lopinavir/r + 2 NRTIs STUDY PROCEDURES: A baseline HIV-RNA, CD4 and routine labs will be collected if the most recent results are not collected within the 4 weeks prior entering the study. Patients will be followed for HIV-RNA (and CD4) at w1, w4, w8, w16, w24, w 36 and w48. After w48, durability of response to lopinavir/r single-drug therapy will be studied long-term (up to w96). Routine hematology and clinical chemistry (including fasting triglycerides and cholesterol, total and HDL/LDL ratio) will be measured at w4, w16, w24, w 36 and w48. A central laboratory will be used for HIV-RNA determinations and to archive plasma/cell samples for further genotype test in case of rebound. Treatment adherence will be followed with a self-patient report questionnaire (GEEMA study) All AEs will be collected if suspected relation (possible or probable) to any concomitant ARV drug, and SAEs, related or not, reported within 24h.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

200

Conditions

HIV Infection

Interventions

Stopping nucleosides and continuing lopinavir/ritonavir monotherapyDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HIV patients \> 18 years old who provide signed and dated Informed consent. * HIV patients who have been receiving lopinavir/ritonavir and two nucleosides during at least 4 weeks. * Plasma HIV RNA \< 50 cop/ml for six months Exclusion Criteria: * HIV patients who have stopped a protease inhibitor due to virological failure. * HIV patients with hepatic or renal insufficiency. * HIV patients with positive serum HBVAg * HIV patients who require treatment with a lopinavir/r contraindicated medication. * HIV pregnant or breastfeeding women. * Active drug abuse (including alcohol or recreational drugs). Exception, cannabis, provided the investigator is confident in patient adherence. Patients under Methadone program will be accepted too if deemed appropriate by the investigator.

Locations (28)

Hospital General de Alicante

Outcomes

Primary Outcomes

% patients with therapeutic failure in both arms at 48 weeks (OT and ITT)

Secondary Outcomes

% patients with virological failure: HIV-RNA > 500 cop/ml under the randomly assigned therapy (OT and ITT)

% patients with HIV RNA < 500 cop/ml and < 50 cop/ml at w24, w48 (OT and ITT)

Time to virological failure per Kaplan Meyer analysis

CD4 cell count change from baseline

Percentage of viruses with resistance in the protease gene at w24 and w48

Description of AEs with probable, possible or unknown relationship to study drug

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.